{"log_id": 1745497935593562168, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 0.035358, "average": 0.879514, "min": 0.441664}, "location": {"width": 397, "top": 209, "height": 28, "left": 167}, "words": "分别为4.6vs4.2个月和19.3v823.9个月"}, {"probability": {"variance": 4.9e-05, "average": 0.992744, "min": 0.982301}, "location": {"width": 96, "top": 251, "height": 27, "left": 167}, "words": "联合用药"}, {"probability": {"variance": 0.015789, "average": 0.944004, "min": 0.376218}, "location": {"width": 786, "top": 291, "height": 29, "left": 193}, "words": "项随机Ⅱ研究(PM259CA220)中,在139位之前接受过蒽环类药物治疗"}, {"probability": {"variance": 7.8e-05, "average": 0.995399, "min": 0.961016}, "location": {"width": 814, "top": 321, "height": 29, "left": 166}, "words": "的转移性乳腺癌患者中比较诺维本软胶囊和卡培他滨联合用药、诺维本软胶囊"}, {"probability": {"variance": 0.001063, "average": 0.985268, "min": 0.850883}, "location": {"width": 637, "top": 351, "height": 30, "left": 165}, "words": "和卡培他滨序贯疗法以及多西他赛和卡培他滨联合用药的疗效"}, {"probability": {"variance": 0.000179, "average": 0.993477, "min": 0.923339}, "location": {"width": 816, "top": 394, "height": 27, "left": 164}, "words": "两个联合用药组,诺维本软胶囊和卡培他滨(V+C)与多西他赛和卡培他滨(D+C"}, {"probability": {"variance": 0.017349, "average": 0.925703, "min": 0.472204}, "location": {"width": 807, "top": 425, "height": 27, "left": 163}, "words": "疾病控制率相似(T人群70.5%对70.8%),缓解率相似(3.%对35%)"}, {"probability": {"variance": 0.025035, "average": 0.912858, "min": 0.373918}, "location": {"width": 813, "top": 456, "height": 26, "left": 167}, "words": "无进展生存期相似(7.2个月对8.9个月),至疗失败时间相似(5.6个月对"}, {"probability": {"variance": 0.01483, "average": 0.95082, "min": 0.357086}, "location": {"width": 812, "top": 486, "height": 28, "left": 167}, "words": "个月)。相较交于先给予诺维本软胶囊然后给予卡培他滨(V←)的序贯治疗方"}, {"probability": {"variance": 0.00109, "average": 0.98661, "min": 0.814202}, "location": {"width": 815, "top": 517, "height": 28, "left": 161}, "words": "案,其所有考虑的有效性参数均劣于联合给药方案。V+C,VtC和D+C组的"}, {"probability": {"variance": 0.008512, "average": 0.947161, "min": 0.653688}, "location": {"width": 818, "top": 546, "height": 32, "left": 159}, "words": "中位总生存期95%C1分别为22.2个月[18.829.9],19.4个月[12.5;35.4]和"}, {"probability": {"variance": 0.009234, "average": 0.939225, "min": 0.639747}, "location": {"width": 224, "top": 577, "height": 28, "left": 159}, "words": "24.2个月[14.2;38.5]"}, {"probability": {"variance": 0.017729, "average": 0.944401, "min": 0.448512}, "location": {"width": 812, "top": 617, "height": 29, "left": 163}, "words": "维软胶囊联舍其他细胞毒药物已经在联合下列药物的1/I期试验中进行了"}, {"probability": {"variance": 9.9e-05, "average": 0.993568, "min": 0.942747}, "location": {"width": 813, "top": 648, "height": 29, "left": 163}, "words": "评估:表柔比星(研究PM259CA205)、多西他赛(PM259CA101)、紫杉醇"}, {"probability": {"variance": 0.001363, "average": 0.987468, "min": 0.77528}, "location": {"width": 798, "top": 680, "height": 28, "left": 177}, "words": "PM259CA102)。诺维本软胶囊和长春瑞滨注射剂交替联合表阿霉素或多西"}, {"probability": {"variance": 1.7e-05, "average": 0.997566, "min": 0.985849}, "location": {"width": 475, "top": 711, "height": 27, "left": 159}, "words": "他赛两种治疗方案显示相似的缓解率,约50%"}, {"probability": {"variance": 0.070214, "average": 0.817107, "min": 0.362575}, "location": {"width": 94, "top": 753, "height": 26, "left": 158}, "words": "中国研"}, {"probability": {"variance": 0.034816, "average": 0.849517, "min": 0.385054}, "location": {"width": 815, "top": 794, "height": 30, "left": 157}, "words": "133位转性斑患者进行一项期随机(1)究,评估诺缤本"}, {"probability": {"variance": 0.038541, "average": 0.868125, "min": 0.391222}, "location": {"width": 744, "top": 826, "height": 31, "left": 156}, "words": "文第一个疗程的第1天和第8天给予601mx13,3周为一疗程"}, {"probability": {"variance": 0.046021, "average": 0.749428, "min": 0.402489}, "location": {"width": 693, "top": 857, "height": 27, "left": 157}, "words": "好天给剂量增器0户1m2与表出星联治疗应)"}, {"probability": {"variance": 0.02066, "average": 0.907667, "min": 0.481058}, "location": {"width": 827, "top": 881, "height": 35, "left": 153}, "words": "输注(第一个疗程的第1天和第8天给予25m2g1m2,3周为一疗程,后续疗"}, {"probability": {"variance": 0.005354, "average": 0.982131, "min": 0.541732}, "location": {"width": 818, "top": 915, "height": 32, "left": 156}, "words": "第1天和第8天给予剂量增至30mg/m2)与表柔比星联合治疗(B组)的有效性"}, {"probability": {"variance": 0.010802, "average": 0.971766, "min": 0.535071}, "location": {"width": 794, "top": 946, "height": 31, "left": 155}, "words": "和安全性。主要疗效终点为客观缓解率。独立审评委员会(IR配文评价结果显示"}, {"probability": {"variance": 0.009365, "average": 0.97468, "min": 0.395386}, "location": {"width": 819, "top": 979, "height": 30, "left": 155}, "words": "在133位接受随机分组治疗的患者中69位(51.9%)显示客观缓解。A组的观"}, {"probability": {"variance": 0.027786, "average": 0.893212, "min": 0.370544}, "location": {"width": 794, "top": 1010, "height": 30, "left": 153}, "words": "缓解为50%(C195%[374-62.6)和B组的客观缓解53.7%(C19541-66.0"}, {"probability": {"variance": 0.011529, "average": 0.936069, "min": 0.607734}, "location": {"width": 714, "top": 1042, "height": 27, "left": 158}, "words": "评价的两组的疾病控制(PR小SD)分别为:组86.4%(C195%75"}, {"probability": {"variance": 0.034306, "average": 0.788374, "min": 0.434569}, "location": {"width": 379, "top": 1071, "height": 27, "left": 156}, "words": "排组%(5%77.8-94.7"}, {"probability": {"variance": 0.002717, "average": 0.980972, "min": 0.743471}, "location": {"width": 817, "top": 1112, "height": 29, "left": 154}, "words": "次疗效参数,中位治疗失败时间(T人群)也显示有类似结果。研究者评价"}, {"probability": {"variance": 0.027321, "average": 0.840856, "min": 0.386252}, "location": {"width": 824, "top": 1144, "height": 29, "left": 152}, "words": "结果显,红为45个月(95%C3.75.0)组为4.6个月(95%C142-5.01)"}, {"probability": {"variance": 0.021612, "average": 0.939386, "min": 0.364798}, "location": {"width": 813, "top": 1185, "height": 26, "left": 153}, "words": "其中位中国患者(A组26位,B组17位)进行长春瑞滨的药代动力学研"}, {"probability": {"variance": 0.000186, "average": 0.994677, "min": 0.935263}, "location": {"width": 818, "top": 1214, "height": 29, "left": 152}, "words": "究。在静脉输注和口服组,中国和欧洲人群间未显示有种族差异,也未观察到表"}, {"probability": {"variance": 1e-06, "average": 0.999182, "min": 0.996391}, "location": {"width": 407, "top": 1246, "height": 28, "left": 151}, "words": "比星对长春瑞滨的药代动力学的影响"}, {"probability": {"variance": 0.007556, "average": 0.573011, "min": 0.486083}, "location": {"width": 69, "top": 1252, "height": 39, "left": 852}, "words": "国康"}, {"probability": {"variance": 0.044426, "average": 0.893351, "min": 0.471802}, "location": {"width": 134, "top": 1288, "height": 27, "left": 156}, "words": "药理毒理翼"}, {"probability": {"variance": 0, "average": 0.904482, "min": 0.904482}, "location": {"width": 37, "top": 1263, "height": 41, "left": 914}, "words": "("}, {"probability": {"variance": 0.009578, "average": 0.910879, "min": 0.763804}, "location": {"width": 97, "top": 1332, "height": 28, "left": 151}, "words": "药理作用"}, {"probability": {"variance": 0.002023, "average": 0.990658, "min": 0.741314}, "location": {"width": 785, "top": 1365, "height": 37, "left": 196}, "words": "长春瑞滨是长春花生物碱家族中的一种抗肿瘤药物,与其它所有长春花生"}, {"probability": {"variance": 0.003109, "average": 0.977938, "min": 0.73983}, "location": {"width": 794, "top": 1403, "height": 30, "left": 149}, "words": "物碱不同的是,长春瑞滨的长春质碱部分经结构修饰。在分子水平,它作"}, {"probability": {"variance": 0.021547, "average": 0.923848, "min": 0.455958}, "location": {"width": 816, "top": 1433, "height": 31, "left": 150}, "words": "了细胞的微管结构中微管蛋白的动态平衡。它抑制微管蛋白的聚合作用,优先"}, {"probability": {"variance": 0.003042, "average": 0.984569, "min": 0.679167}, "location": {"width": 817, "top": 1479, "height": 36, "left": 149}, "words": "与有丝分裂微管进行结合,可阻断细胞从G2期进入M期。本药除了作用于"}, {"probability": {"variance": 0.036456, "average": 0.895253, "min": 0.375071}, "location": {"width": 641, "top": 1542, "height": 33, "left": 198}, "words": "的微管以外,作用于鲁突微管,故可引起神经毒性"}], "language": 3}